GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

Virax Biolabs Group VRAX · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.71

-10.35%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Virax Biolabs Group — daily VRAX Delayed
Market value
$5.3m
Last close × shares
Volume
348.2k
Shares, 9 Nov 2026

About Virax Biolabs Group

Its shares trade under the ticker VRAX. It has been listed since 14 July 2022. In the fiscal year to 31 March 2026, it reported revenue of $12,423 and a net loss of $5.0m. At that date it held total assets of $8.3m and shareholders' equity of $7.6m.

Virax Biolabs Group Ltd. is a holding company, which engages in the sale, distribution, and marketing of diagnostics test kits and med-tech and personal protective equipment products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The firm is primarily engaged in the sales, distribution and marketing of diagnostics test kits and medical technology for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The company is developing a T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral threats. Its product portfolio includes: ViraxClear and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus. Its T-Cell testing is effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.

Figures and description from our data supplier, not checked against the company's own report.

More about Virax Biolabs Group →

Latest on Virax Biolabs Group

Our reporting

We have not reported on Virax Biolabs Group yet.

Next results

2 Dec 2026

Due on 2 Dec 2026. Analysts expect earnings of -1.75 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Virax Biolabs Group's ticker?

Virax Biolabs Group trades as VRAX on its US listing, under ISIN KYG9495L1251.

What was Virax Biolabs Group's last closing price?

0.71 on 9 Nov 2026. The figure is in USD and is never converted.

When does Virax Biolabs Group next report results?

Results are expected on 2 Dec 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.